• Policy
• Reimb of PE exemption drugs can be ex officio rejected
• by Lee, Tak-Sun Dec 16, 2024 05:53am

• Policy
• NHIS to expand the special estimate case system in 2025
• by Lee, Tak-Sun Dec 16, 2024 05:52am

• Policy
• HLB Pharma applies for reimb of 'Citrelin ODT' for SCD
• by Lee, Tak-Sun Dec 16, 2024 05:52am

• Policy
• Otezla generics enter negotiations for reimb
• by Lee, Tak-Sun Dec 13, 2024 05:52am

• Policy
• Martial law impacts the launch of the Pharma-Bio Committee
• by Lee, Jeong-Hwan Dec 13, 2024 05:51am

• Policy
• HIRA sets plan for performance assessment of 'Qarziba'
• by Lee, Tak-Sun Dec 12, 2024 05:49am

• Policy
• New drug approval fee to rise next year
• by Lee, Hye-Kyung Dec 12, 2024 05:49am

• Policy
• Cancellation policy for innovative pharmas certification
• by Kang, Shin-Kook Dec 9, 2024 05:47am

• Policy
• Janssen seeks reimb for Balversa in Korea
• by Lee, Tak-Sun Dec 9, 2024 05:46am

• Policy
• Reimb extension discussions for Kyprolis break down
• by Lee, Tak-Sun Dec 6, 2024 05:57am